NuVision Biotherapies announces the appointment of its new Chief Executive Officer and Chief Operating Officer

Andy Hill and Noel Waters join the expanding NuVision Team. Andy is appointed as Chief Executive Officer and Noel as Chief Operating Officer as the Company plans for their next stage of international growth

Today, NuVision Biotherapies, the developer of Tereo-processed amniotic membrane-based products for use in ophthalmology and wider wound care, announces the appointment of Andy Hill as its Chief Executive Officer, as the company prepares to expand the business for its next stage of growth. Andy joins NuVision with over 35 years’ experience in the European and US medical device industry and has both entrepreneurial and hands-on experience of building early-stage businesses bringing new and disruptive technologies to international markets.

It is a privilege to be invited to join NuVision as CEO. I look forward to working with the NuVision team and building on the great foundations that have been laid since the company was spun out of the University of Nottingham in 2015. Omnigen is an exciting, proven product that is already making a real difference, helping patients with complex, hard to heal wounds recover” commented Andy Hill.

Andy’s previous experience includes co-founding and launching Intelligent Ultrasound Limited out of the University of Oxford in 2010, providing first-hand experience of technology transfer and the UK university spin-out environment. Andy was one of the key leaders in taking PercuSurge Inc. from first-in-man trials to their $225m trade sale to Medtronic Inc. He leaves AI-based imaging analytics business Sēon Diagnostics limited to join NuVision.

Commenting further on Andy’s appointment, Dr Mark Treherne, Chairperson of NuVision Biotherapies, added “Andy joins us at an exciting time of growth and development, as we are broadening our international expansion. He brings a plethora of relevant commercial experience in growing and expanding early-stage businesses. NuVision is delighted to welcome him into the business as its new leader”.

Noel Waters has also joined the NuVision Biotherapies team to develop, scale and support our patented Tereo® manufacturing process. Noel will be leading NuVision’s Operations Group as the company scales and grows manufacturing capacity of their tissue-based therapies. He joins the NuVision Biotherapies team, who develop Tereo processed amniotic membrane-based products for use in the ophthalmology and wider wound care market.

Commenting on Noel’s appointment, Mark Treherne added “we are privileged to have attracted Noel to join us at this pivotal stage in our development, as we scale for international expansion. Noel’s experience and track record speak for themselves.”

Noel has many years of delivering for major global manufacturing businesses, previously working for Smith & Nephew PLC as Senior Vice President of Global Operations (Advanced Wound Management). Most recently, Noel has become both the Proprietor and Director of HTNW Limited, an Interim Operations Management and Consultancy focused on the medical device sector. Noel has over 35 years’ experience establishing highly successful manufacturing and supply chain operations from concept to execution, in multiple regions including both China and India and joined NuVision on the 2nd November 2021. 

I am delighted to be joining the management team at this critical and exciting time in the development of the business. Scaling the manufacture of Tereo-processed amniotic membrane-based products is essential to enabling the Company to expand globally” added Noel Waters.  

NuVision would like to extend the warmest of welcomes to Andy and Noel to the team. If you would like more information on NuVision, please visit: or email:

NuVision Biotherapies 

Based in MediCity, Nottingham, NuVision Biotherapies is a regenerative medicine company spun out from the University of Nottingham. NuVision was established in 2015, founded on investment from Mercia Fund Management, to develop and bring to market cutting edge, regenerative therapies.

About Omnigen

Omnigen Tereo processed amniotic membrane, is a patented dry preparation of human amniotic membrane.  Amniotic membrane is the innermost layer of the placental sac, which protects and holds the foetus during pregnancy.  NuVision upcycles and transforms this waste product of birth into an effective wound care product.

The Tereo manufacturing process, developed at the University of Nottingham’s Academic Ophthalmology department, transforms this waste product of birth into a sterile and stable dry regenerative therapy that can be easily shipped and accessed anywhere in the world. Omnigen is applied directly to the wound dry and is rapidly and effectively rehydrated using surrounding moisture to immediately reactivate the beneficial properties to promote tissue repair and healing in a variety of ways.

The product represents a unique and versatile “off-the-shelf” regenerative product, and it may be stored long-term. The Tereo process preserves the wound healing action and provides surgeons with an effective sight saving therapy that could provide a meaningful benefit to patients, including those suffering from ocular surface disease and conditions with unmet medical need.

About OmniLenz 

OmniLenz is a bespoke BCL designed to apply and hold Omnigen at the ocular surface without the need for sutures or surgery. OmniLenz is manufactured exclusively for NuVision by Menicon, UK. Omnigen can be applied by OmniLenz using a simple 4 – 6-minute procedure in an outpatient setting. The decision to apply Omnigen to the ocular surface using OmniLenz is at the discretion of the clinician.

Continue reading: